Results 1 to 10 of about 43,266 (250)
Pathophysiology of Portal Hypertension and Esophageal Varices [PDF]
International Journal of Hepatology, 2012 Esophageal varices are the major complication of portal hypertension. It is detected in about 50% of cirrhosis patients, and approximately 5–15% of cirrhosis patients show newly formed varices or worsening of varices each year.
Hitoshi Maruyama, Osamu Yokosuka
doaj +2 more sources
Journal of Clinical Interventional Radiology ISVIRBleeding ileal varices are rare in liver cirrhosis, where the gastroesophageal varices frequently accompany ectopic varices. Small bowel varices usually develop in patients with a history of abdominal surgery.
Suhas D. Wagle +3 more
doaj +2 more sources
NON-INVASIVE TOOLS TO ASSESS THE RISK OF VARICES-NEEDING-TREATMENT IN CIRRHOSIS SECONDARY TO HCV
Pakistan Armed Forces Medical Journal, 2021 Objective: To assess the non-invasive biomarkers of fibrosis for predicting varices-needing-treatment in patients with cirrhosis secondary to chronic-hepatitis-C. Study Design: Cross sectional comparative study.
Laima Alam, Farrukh Saeed
doaj +3 more sources
Efficiency and Safety of Endoscopic Injection Sclerotherapy With Ligation for Esophageal Varices: A Retrospective Study. [PDF]
DEN OpenABSTRACT Objectives Endoscopic injection sclerotherapy with ligation (EISL) is a combined endoscopic treatment that involves endoscopic injection sclerotherapy (EIS) and endoscopic variceal ligation. This study aimed to compare the efficacy of conventional EIS and EISL in treating esophageal varices and the usefulness of EISL.
Maki K +6 more
europepmc +2 more sources
Insights into pelvic venous disorders
Frontiers in Cardiovascular Medicine, 2023 Pelvic venous disorders (PeVD), sometimes referred to as pelvic congestion syndrome (PCS), widely impact affected patients–mainly young women’s quality of life, causing puzzling, uncomfortable symptoms sometimes requiring months or years to get an ...
Kiara Rezaei-Kalantari +3 more
doaj +1 more source
Frontiers in Oncology, 2022 Recently, a combined regimen of atezolizumab and bevacizumab (AB) treatment has been approved as a first-line treatment in patients with advanced hepatocellular carcinoma (HCC), contributing to prolonged survival.
Hiroyuki Suzuki +12 more
doaj +1 more source
Management of Varices and Variceal Hemorrhage in Cirrhosis [PDF]
New England Journal of Medicine, 2010 Variceal hemorrhage is a lethal complication of cirrhosis, particularly in patients in whom clinical decompensation (i.e., ascites, encephalopathy, a previous episode of hemorrhage, or jaundice) has already developed. Practice guidelines for the management of varices and variceal hemorrhage1 in cirrhosis are mostly based on evidence in the literature ...
Garcia Tsao, Guadalupe +1 more
openaire +3 more sources
Hepatology, EarlyView., 2022 A deleterious variant of FCHSD1 results in mTOR pathway overactivation and may cause porto‐sinusoidal vascular disorder (PSVD). The pedigree of the family demonstrated an autosomal dominant disease with variable expressivity. Whole‐genome sequencing and Sanger sequencing both validated the existence of the FCHSD1 variant and the heterozygosity of c ...
Jingxuan Shan +19 more
wiley +1 more source
Indian Pediatrics Case Reports, 2023 Background: Umbilical vein catheterization is a routine procedure in neonatal intensive care units. This invasive procedure, though easy and useful, can result in disastrous complications.
Surbhi Latawa +3 more
doaj +1 more source
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source